ALEC
Alector, Inc.
$2.08
+0.06
(+2.97%)
Mkt Cap
230.93M
Volume
3,087,512
52W Range
1.09-3.4
Sector
Healthcare
Beta
0.62
EPS (TTM)
-1.10 USD
P/E Ratio
-1.12
Revenue (TTM)
13.86M USD
Rev Growth (5Y)
-0.1%
EPS Growth (5Y)
N/A
Company Description
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.05M | 100.56M | 97.06M | 133.62M | 207.09M | 21.10M | 21.22M | 27.68M | 3.73M | 416,000 |
| Net Income | (142.93M) | (119.05M) | (130.39M) | (133.31M) | (36.33M) | (190.23M) | (105.39M) | (52.25M) | (32.48M) | (15.11M) |
| EPS | -1.39 | -1.23 | -1.56 | -1.62 | -0.45 | -2.45 | -1.62 | -0.76 | -0.63 | -1.78 |
| Free Cash Flow | (184.07M) | (231.16M) | (186.54M) | (24.45M) | 295.30M | (171.77M) | (114.57M) | 125.58M | (18.57M) | (15.24M) |
| FCF / Share | -1.79 | -2.39 | -2.23 | -0.30 | 3.67 | -2.21 | -1.86 | 1.84 | -0.36 | -1.79 |
| Operating CF | (184.03M) | (229.91M) | (184.16M) | (20.33M) | 298.55M | (166.73M) | (99.31M) | 127.46M | (17.77M) | (12.99M) |
| Total Assets | 293.24M | 468.30M | 621.83M | 787.65M | 814.66M | 488.25M | 421.91M | 308.36M | 236.06M | 54.11M |
| Total Debt | 36.23M | 42.52M | 38.92M | 43.33M | 47.60M | 51.26M | 48.04M | 0 | 0 | 0 |
| Cash & Equiv | 65.80M | 33.02M | 74.56M | 154.32M | 329.15M | 49.97M | 89.64M | 65.47M | 32.45M | 50.84M |
| Book Value | 30.65M | 126.80M | 134.16M | 214.44M | 300.72M | 267.53M | 194.74M | (97.40M) | (52.03M) | (24.91M) |
| Return on Equity | -4.66 | -0.94 | -0.97 | -0.62 | -0.12 | -0.71 | -0.54 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.32M | 1.05M | 6.24M | 3.26M | 7.87M | 3.67M | 54.24M | 15.34M | 15.08M | 15.89M | 15.19M | 9.11M |
| Net Income | (22.99M) | (22.93M) | (37.27M) | (34.67M) | (30.52M) | (40.47M) | (2.07M) | (42.22M) | (38.68M) | (36.08M) | (41.43M) | (44.48M) |
| EPS | -0.21 | -0.21 | -0.34 | -0.34 | -0.30 | -0.41 | -0.02 | -0.43 | -0.40 | -0.38 | -0.49 | -0.53 |
| Free Cash Flow | (34.25M) | (49.93M) | (41.69M) | (32.52M) | (49.06M) | (60.80M) | (55.20M) | (50.95M) | (63.13M) | (61.88M) | (46.30M) | (46.45M) |
| FCF / Share | -0.31 | -0.45 | -0.40 | -0.32 | -0.49 | -0.61 | -0.57 | -0.52 | -0.65 | -0.66 | -0.55 | -0.55 |
| Operating CF | (34.22M) | (49.81M) | (41.69M) | (32.51M) | (49.05M) | (60.78M) | (55.03M) | (50.73M) | (62.80M) | (61.35M) | (46.07M) | (46.54M) |
| Total Assets | 202.85M | 239.92M | 293.24M | 335.29M | 356.42M | 408.30M | 468.30M | 516.02M | 570.73M | 635.49M | 621.83M | 672.39M |
| Total Debt | 32.76M | 34.55M | 36.23M | 37.88M | 39.48M | 41.05M | 42.52M | 34.64M | 36.11M | 37.56M | 38.92M | 40.23M |
| Cash & Equiv | 59.91M | 76.96M | 65.80M | 76.50M | 44.77M | 37.97M | 33.02M | 37.16M | 47.55M | 72.55M | 74.56M | 101.96M |
| Book Value | (9.97M) | 10.38M | 30.65M | 57.71M | 71.17M | 94.61M | 126.80M | 118.93M | 150.57M | 178.91M | 134.16M | 162.56M |
| Return on Equity | N/A | -2.21 | -1.22 | -0.60 | -0.43 | -0.43 | -0.02 | -0.35 | -0.26 | -0.20 | -0.31 | -0.27 |
ALEC News
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases
Contrasting Alector (NASDAQ:ALEC) & Ionis Pharmaceuticals (NASDAQ:IONS)
Alector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Comparing Alector (NASDAQ:ALEC) and Sarepta Therapeutics (NASDAQ:SRPT)
Alector to Participate in Upcoming Healthcare Conferences
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Alector and GSK partnership to end after dementia, Alzheimer's drug failures